378 related articles for article (PubMed ID: 32506369)
1. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
Malani R; Fleisher M; Kumthekar P; Lin X; Omuro A; Groves MD; Lin NU; Melisko M; Lassman AB; Jeyapalan S; Seidman A; Skakodub A; Boire A; DeAngelis LM; Rosenblum M; Raizer J; Pentsova E
J Neurooncol; 2020 Jul; 148(3):599-606. PubMed ID: 32506369
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases.
Diaz M; Singh P; Kotchetkov IS; Skakodub A; Meng A; Tamer C; Young RJ; Reiner AS; Panageas KS; Ramanathan LV; Pentsova E
J Neurooncol; 2022 Mar; 157(1):81-90. PubMed ID: 35113288
[TBL] [Abstract][Full Text] [Related]
3. Integration of rare cell capture technology into cytologic evaluation of cerebrospinal fluid specimens from patients with solid tumors and suspected leptomeningeal metastasis.
Torre M; Lee EQ; Chukwueke UN; Nayak L; Cibas ES; Lowe AC
J Am Soc Cytopathol; 2020; 9(1):45-54. PubMed ID: 31606331
[TBL] [Abstract][Full Text] [Related]
4. Detection of Circulating Tumor Cells in Cerebrospinal Fluid of Patients with Suspected Breast Cancer Leptomeningeal Metastases: A Prospective Study.
Darlix A; Cayrefourcq L; Pouderoux S; Menjot de Champfleur N; Bievelez A; Jacot W; Leaha C; Thezenas S; Alix-Panabières C
Clin Chem; 2022 Oct; 68(10):1311-1322. PubMed ID: 35953885
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.
Lin X; Fleisher M; Rosenblum M; Lin O; Boire A; Briggs S; Bensman Y; Hurtado B; Shagabayeva L; DeAngelis LM; Panageas KS; Omuro A; Pentsova EI
Neuro Oncol; 2017 Sep; 19(9):1248-1254. PubMed ID: 28821205
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
Zagouri F; Zoumpourlis P; Le Rhun E; Bartsch R; Zografos E; Apostolidou K; Dimopoulos MA; Preusser M
Cancer Treat Rev; 2020 Aug; 88():102046. PubMed ID: 32599393
[TBL] [Abstract][Full Text] [Related]
7. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Bonneau C; Paintaud G; Trédan O; Dubot C; Desvignes C; Dieras V; Taillibert S; Tresca P; Turbiez I; Li J; Passot C; Mefti F; Mouret-Fourme E; Le Rhun E; Gutierrez M
Eur J Cancer; 2018 May; 95():75-84. PubMed ID: 29635147
[TBL] [Abstract][Full Text] [Related]
8. HER2-targeted therapy influences CTC status in metastatic breast cancer.
Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
[TBL] [Abstract][Full Text] [Related]
9. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
Oberkampf F; Gutierrez M; Trabelsi Grati O; Le Rhun É; Trédan O; Turbiez I; Kadi A; Dubot C; Taillibert S; Vacher S; Bonneau C
Neuro Oncol; 2023 Feb; 25(2):365-374. PubMed ID: 35868630
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Ignatiadis M; Litière S; Rothe F; Riethdorf S; Proudhon C; Fehm T; Aalders K; Forstbauer H; Fasching PA; Brain E; Vuylsteke P; Guardiola E; Lorenz R; Pantel K; Tryfonidis K; Janni W; Piccart M; Sotiriou C; Rack B; Pierga JY
Ann Oncol; 2018 Aug; 29(8):1777-1783. PubMed ID: 29893791
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
14. Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration.
Le Tilly O; Azzopardi N; Bonneau C; Desvignes C; Oberkampf F; Ezzalfani M; Ternant D; Turbiez I; Gutierrez M; Paintaud G
Clin Pharmacol Ther; 2021 Jul; 110(1):210-219. PubMed ID: 33547646
[TBL] [Abstract][Full Text] [Related]
15. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases.
van Bussel MTJ; Pluim D; Milojkovic Kerklaan B; Bol M; Sikorska K; Linders DTC; van den Broek D; Beijnen JH; Schellens JHM; Brandsma D
Neurology; 2020 Feb; 94(5):e521-e528. PubMed ID: 31907288
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
17. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.
Patel AS; Allen JE; Dicker DT; Peters KL; Sheehan JM; Glantz MJ; El-Deiry WS
Oncotarget; 2011 Oct; 2(10):752-60. PubMed ID: 21987585
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Kumthekar PU; Avram MJ; Lassman AB; Lin NU; Lee E; Grimm SA; Schwartz M; Bell Burdett KL; Lukas RV; Dixit K; Perron I; Zhang H; Gradishar WJ; Pentsova EI; Jeyapalan S; Groves MD; Melisko M; Raizer JJ
Neuro Oncol; 2023 Mar; 25(3):557-565. PubMed ID: 35948282
[TBL] [Abstract][Full Text] [Related]
19. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
